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Reporting of birth defects in SART CORS: time to rely on data 
linkage
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In this issue of Fertility and Sterility, Stern et al. (1) assessed the validity of the birth 
outcome data reported to the Society for Assisted Reproductive Technology Clinic Outcome 
Reporting System (SART CORS) compared with the outcome data from vital records and 
the Massachusetts Birth Defects Monitoring Program (BDMP), the statewide population-
based active birth defects surveillance system for a cohort of 9,092 assisted reproductive 
technology (ART) deliveries from 2004 to 2008 in Massachusetts. Compared with vital 
records, the SART CORS does a great job of reporting for some outcomes, with >99% 
concordance on delivery outcome (live birth/fetal death) and plurality. More than 90% of 
birth dates match, and most singleton birth weights (87%) are different by <50 g. Maternal 
race/ethnicity is missing two-thirds of the time in SART CORS, but when not missing, it is 
reasonably accurate, with 95% concordance. So far, so good. When we look at birth defects, 
it is entirely another matter.
The SART CORS reported 135 birth defects among 132 infants compared with 184 birth 
defects among 132 infants in the BDMP data. Although it seems at first glance that we 
might still be on fairly solid ground with the same number of infants identified; the problem 
was that only 51 infants were identified with birth defects in both datasets. Overall, SART 
CORS is missing 81 infants (61%) that have birth defects confirmed by BDMP, and a 
corresponding 81 cases in the SART CORS are unconfirmed by BDMP. Compared with the 
active surveillance of the BDMP as the criterion standard, ART clinics appear to be missing 
the mark. The problem starts with the categories of birth defects reported in SART CORS; 
rather than capturing diagnostic codes or detailed information, the system allows for the 
following predefined categories, with no instruction provided as to which specific diagnoses 
are to be considered as relevant to a given category: none, unknown, cleft palate, genetic 
defect, limb defect, cardiac defect, and other. Given these limited and undefined categories, 
and that the SART CORS data come from a variety of reporting sources, including medical 
records, provider reports and parent self-reports, it is not surprising that there are 
inaccuracies. We were a bit surprised to see that the errors went in both directions, with 
similar numbers of false positives and false negatives.
Major birth defects are common in aggregate, generally affecting ~3% of births (2), but 
specific birth defects are relatively rare. The most common defects are congenital heart 
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defects (CHDs), with an overall prevalence of nearly 1% (3, 4), or approximately one-third 
of all babies with birth defects. But not all CHDs are diagnosed during the birth 
hospitalization. We might expect the SART CORS to underreport CHDs, and they do, with 
11 cases (28%) compared with 40 in the BDMP. SART CORS also reports 14 unconfirmed 
CHDs, perhaps due to “rule out” conditions that were reported to the clinics but ultimately 
determined to be noncases. The Stern et al. report shows that reporting is not better for other 
defects. Sensitivity for specific defect groups ranges from 18% to 50%, and attempts to try 
and reconcile misclassified cases by means of searching vital records did not help resolve 
discrepancies.
Whether ART increases birth defect risk is an important question. In population research, 
two things drive the ability to see a significant effect: sample size and effect size. In this 
case, if the effects were large, they should be apparent by now, given the increased use of 
ART around the globe. So, let us suppose that the effects are small (if present at all) or 
effects are there for only a subgroup of patients. Then these classification errors are likely to 
lead to null results in a scientific investigation.
It seems to be time to question the utility of having ART clinics report birth defects. 
However well intentioned, the collection of these data without consistent methods, with 
limited specificity, and based on a variety of reporting sources is not working. It may not be 
worth the effort to collect and report poor-quality data, as opposed to investing in linkages 
with high-quality birth defects surveillance data. An old professor of one of us (P.M.) used 
to say that “some data beats no data” in public health and prevention, but when the data are 
of poor quality, it is time to consider moving to better systems.
The Centers for Disease Control and Prevention have supported the States Monitoring 
Assisted Reproductive Technology (SMART) Collaborative, which currently includes 
Massachusetts, Florida, Connecticut, and Michigan. This project supports linkage of ART 
data with other data systems, including vital records and birth defects registries (5). In 
addition to including other infant outcomes, this model is a stronger approach for 
surveillance, certainly for rare outcomes, such as birth defects, but also for other infant 
outcomes that are not captured in the current SART system.
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